Market closed

Pliant Therapeutics/$PLRX

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Pliant Therapeutics

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Ticker

$PLRX

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

South San Francisco, United States

Employees

166

Website

pliantrx.com

PLRX Metrics

BasicAdvanced

$684M

-

-$3.34

1.09 -

Price and volume

Market cap

$684M

Beta

1.09

52-week high

$18.92

52-week low

$10.22

Average daily volume

522K

Financial strength

Current ratio

10.263

Quick ratio

10.18

Long term debt to equity

17.318

Total debt to equity

17.412

Interest coverage (TTM)

-88.44%

Management effectiveness

Return on assets (TTM)

-28.15%

Return on equity (TTM)

-47.52%

Valuation

Price to book

1.98

Price to tangible book (TTM)

1.98

Price to free cash flow (TTM)

-4.96

Growth

Revenue change (TTM)

-100.00%

Earnings per share change (TTM)

20.51%

3-year earnings per share growth (CAGR)

9.21%

What the Analysts think about PLRX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Pliant Therapeutics stock.

PLRX Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

PLRX Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

PLRX News

AllArticlesVideos

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PLRX

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Pliant Therapeutics stock?

Pliant Therapeutics (PLRX) has a market cap of $684M as of January 15, 2025.

What is the P/E ratio for Pliant Therapeutics stock?

The price to earnings (P/E) ratio for Pliant Therapeutics (PLRX) stock is 0 as of January 15, 2025.

Does Pliant Therapeutics stock pay dividends?

No, Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Pliant Therapeutics dividend payment date?

Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Pliant Therapeutics?

Pliant Therapeutics (PLRX) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.